Macarena Garrido-Estepa

Mrs. Macarena Garrido-Estepa

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa
FRFrancisco Ruiz-Perales
Francisco Ruiz-Perales
JMJosefa Miranda
Josefa Miranda
NANieves Ascunce
Nieves Ascunce
IGIsabel González-Román
Isabel González-Román
Jesus VioqueJesus Vioque
Jesus Vioque
Background: Increased mammographic breast density is a moderate risk factor for breast cancer. Different scales have been proposed for classifying mammographic density. This study sought to assess intra-rater agreement for the most widely used scales (Wolfe, Tabár, BI-RADS and Boyd) and compare them in terms of classifying mammograms as high- or low-density. Methods: The study covered 3572 mammograms drawn from women included in the DDM-Spain study, carried-out in seven Spanish Autonomous Regions. Each mammogram was read by an expert radiologist and classified using the Wolfe, Tabár, BI-RADS and Boyd scales. In addition, 375 mammograms randomly selected were read a second time to estimate intra-rater agreement for each scale using the kappa statistic. Owing to the ordinal nature of the scales, weighted kappa was computed. The entire set of mammograms (3572) was used to calculate agreement among the different scales in classifying high/low-density patterns, with the kappa statistic being computed on a pair-wise basis. High density was defined as follows: percentage of dense tissue greater than 50% for the Boyd, "heterogeneously dense and extremely dense" categories for the BI-RADS, categories P2 and DY for the Wolfe, and categories IV and V for the Tabár scales. Results: There was good agreement between the first and second reading, with weighted kappa values of 0.84 for Wolfe, 0.71 for Tabár, 0.90 for BI-RADS, and 0.92 for Boyd scale. Furthermore, there was substantial agreement among the different scales in classifying high- versus low-density patterns. Agreement was almost perfect between the quantitative scales, Boyd and BI-RADS, and good for those based on the observed pattern, i.e., Tabár and Wolfe (kappa 0.81). Agreement was lower when comparing a pattern-based (Wolfe or Tabár) versus a quantitative-based (BI-RADS or Boyd) scale. Moreover, the Wolfe and Tabár scales classified more mammograms in the high-risk group, 46.61 and 37.32% respectively, while this percentage was lower for the quantitative scales (21.89% for BI-RADS and 21.86% for Boyd). Conclusions: Visual scales of mammographic density show a high reproducibility when appropriate training is provided. Their ability to distinguish between high and low risk render them useful for routine use by breast cancer screening programs. Quantitative-based scales are more specific than pattern-based scales in classifying populations in the high-risk group.

27 June 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
GZGalliano Zanello
Galliano Zanello
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa
ACAna Crespo
Ana Crespo
DODaniel O'COnnor
Daniel O'COnnor
RNRima Nabbout
Rima Nabbout
PBPhilip John Brooks
Philip John Brooks
Rare diseases affect over 400 million people worldwide and less than 5% of rare diseases have an approved treatment. Fortunately, the number of underlying disease etiologies is far less than the number of diseases, because many rare diseases share a common molecular etiology. Moreover, many of these shared molecular etiologies are therapeutically actionable. Grouping rare disease patients for clinical trials based on the underlying molecular etiology, rather than the traditional, symptom‐based definition of disease, has the potential to greatly increase the number of patients gaining access to clinical trials. Basket clinical trials based on a shared molecular drug target have become common in the field of oncology and have been accepted by regulatory agencies as a basis for drug approvals. Implementation of basket clinical trials in the field of rare diseases is seen by multiple stakeholders—patients, researchers, clinicians, industry, regulators, and funders—as a solution to accelerate the identification of new therapies and address patient's unmet needs.

1 May 2014 in Vaccine
Verified
Journal Article
Closed access
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa
ILI. León-Gómez
I. León-Gómez
RHR. Herruzo
R. Herruzo
RCR. Cano
R. Cano

14 November 2016 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
LGL. Georgalis
L. Georgalis
AMA. Mozalevskis
A. Mozalevskis
MAM. V. Martínez de Aragón
M. V. Martínez de Aragón
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa

20 February 2019 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
Marta Martínez-AvilésMarta Martínez-Avilés
Marta Martínez-Avilés
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa
JAJulio Alvarez
Julio Alvarez
ATAna De La Torrre
Ana De La Torrre
Non-typhoid salmonellosis is a common and problematic foodborne zoonotic disease in which pork and pork products can be an important potential source of infection. To prevent this disease, important efforts to monitor the situation in the main source, livestock, are conducted in most developed countries. In the European Union, European Food Safety Agency (EFSA) and European Center for Disease Control (ECDC) compile information at the member-state level, even though important differences in production systems and surveillance systems exist. Here, Salmonella surveillance systems in one of the main sources of foodborne salmonellosis, swine, and humans in Spain were reviewed to identify potential gaps and discuss potential ways of integration under a “One-Health” approach. Despite the extensive information generated through the surveillance activities, source attribution can be only routinely performed through ad-hoc outbreak investigations, and national reports on human outbreaks do not provide sufficiently detailed information to gain a better understanding of the epidemiology of the pathogen. Human and animal monitoring of Salmonella would benefit from a better exchange of information and collaboration. Analysis of spatio-temporal trends in livestock and humans could help to identify likely sources of infection and to target surveillance efforts in areas with higher prevalence or where specific strains are found.

17 June 2021 in International Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
MPManuel Posada de La Paz
Manuel Posada de La Paz
EDEnrique Díaz-Guerra
Enrique Díaz-Guerra
VAVerónica Alonso-Ferreira
Verónica Alonso-Ferreira
AVAna Villaverde-Hueso
Ana Villaverde-Hueso
GAGreta Arias-Merino
Greta Arias-Merino
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa
Toxic oil syndrome (TOS) is a multisystemic disease due to a massive intoxication that occurred in Spain in 1981 affecting >20 000 persons. This study aims to evaluate the quality of life of the survivors’ cohort after 38 years of follow-up using the Short Form 36 (SF-36) Health Survey. One thousand patients were selected among the 14 084 alive TOS cohort members in 2018 using a stratified random sampling method. Stratification was performed by the 2017 self-rated health status reported by patients. SF-36 results were compared directly and as standardized (T scores) with the Spanish-population reference values. Relationship between self-rated health status and SF-36 results was assessed. Overall, 900 cohort members participated and 895 valid responses were included in the study. Participants’ average age was 65.2 (standard deviation: 13.8) years and 563 (62.9%) participants were women. Participants’ distribution by self-rated health status was: 219 (24.5%) good/very good, 415 (46.4%) fair and 261 (29.1%) poor/very poor. Quality of life was below the Spanish-population reference in 84% of the TOS patients (87.2% for women and 78.6% for men) for the Physical Component Summary (PCS) and in 75.4% (81.7% for women and 64.8% for men) for the Mental Component Summary (MCS). PCS and MCS scores decreased similarly for both sexes with worse self-rated health. Very low quality of life and self-rated health, especially for women, were found in the total TOS participants that can be extrapolated to the TOS survivors’ cohort. The TOS cohort still requires standardization of care with integral plans around the country.